Table 4.
Comparison of serum total fatty acids composition in Hepatitis B patients and controls
| Fatty acids | Controls (g/100 g) (n = 50) | Patients (g/100 g) (n = 50) |
|---|---|---|
| C - 14: 0 | 1.11 ± 0.8 | 2.04 ± 0.6* |
| C - 16: 0 | 21.67 ± 5.8 | 27.95 ± 3.3* |
| C - 18: 0 | 14.27 ± 4.9 | 13.27 ± 5.5 |
| C - 20: 0 | 0.56 ± 0.9 | 0.43 ± 0.3 |
| C – 24: 0 | 0.08 ± 0.2 | 0.10 ± 0.2 |
| C - 14: 1 | 0.44 ± 0.8 | 0.46 ± 0.3 |
| C - 16: 1 | 2.96 ± 2.0 | 3.55 ± 0.8 |
| C - 18: 1 | 20.28 ± 4.4 | 21.64 ± 4.0 |
| C - 22: 1 | 1.74 ± 1.3 | 1.92 ± 0.6 |
| C – 24: 1 | 0.24 ± 0.6 | 0.09 ± 0.2 |
| C - 18: 2 | 26.49 ± 5.0 | 21.48 ± 3.4* |
| C - 18: 3 | 0.90 ± 1.2 | 0.31 ± 0.3 |
| C - 20: 3 | 0.90 ± 1.3 | 0.62 ± 0.3* |
| C - 20: 4 | 6.40 ± 1.9 | 3.72 ± 0.9* |
| C - 20: 5 | 1.08 ± 1.4 | 0.13 ± 0.2* |
| C - 22: 5 | 0.40 ± 0.3 | 0.79 ± 0.5* |
| C - 22: 6 | 0.45 ± 0.4 | 0.41 ± 0.4 |
| PUFA: SFA | 1.0 | 0.6 |
Values are mean ± standard deviation,*shows significant difference from Hepatitis B patients with comparison of healthy controls a p < 0.05 (t- test). myristic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), α-linolenic acid (C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3), arachidonic acid (C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic acid (C22:1), docosahexaenoic acid (DHA (C22:6) lignoceric acid (C24:0), nervonic acid(C24:1)